Khe Hoang-Xuan

Prof. Dr. Khe Hoang-Xuan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
KHKhe Hoang-Xuan
Khe Hoang-Xuan
MDMartina Deckert
Martina Deckert
AFAndrés J M Ferreri
Andrés J M Ferreri
JFJulia Furtner
Julia Furtner
JPJaime Gallego Perez-Larraya
Jaime Gallego Perez-Larraya
JBJacoline E C Bromberg
Jacoline E C Bromberg
The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.

1 May 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
GTGuillaume Taieb
Guillaume Taieb
EKElsa Kaphan
Elsa Kaphan
CDClaire Duflos
Claire Duflos
CLChristine Lebrun-Frénay
Christine Lebrun-Frénay
VRValerie Rigau
Valerie Rigau
GBGeneviève de Saint Basile
Geneviève de Saint Basile
Objective To determine whether adult cases of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS) may be related to familial hemophagocytic lymphohistiocytosis (HLH) causes, we have screened patients with adult-onset CLIPPERS for mutations in primary HLH-associated genes. Methods In our cohort of 36 patients fulfilling the criteria for probable or definite CLIPPERS according to the CLIPPERS-2017 criteria, we conducted a first study on 12 patients who consented to genetic testing. In these 12 patients, systemic HLH criteria were searched, and genetic analysis of 8 genes involved in primary HLH was performed. Results Four definite and 8 probable CLIPPERS were enrolled (n = 12). Mutations involved in HLH were identified in 2 definite and 2 probable CLIPPERS (4/12). Three of them had biallelic PRF1 mutations with reduced perforin expression in natural killer cells. The remaining patient had biallelic UNC13D mutations with cytotoxic lymphocyte impaired degranulation. None of the mutated patients reached the criteria for systemic HLH. During follow-up, 3 of them displayed atypical findings for CLIPPERS, including emergence of systemic non-Hodgkin lymphoma (1/3) and confluent gadolinium-enhancing lesions on brain MRI (3/3). Conclusions In our patients presenting with adult-onset CLIPPERS, one-third have HLH gene mutations. This genetic treatable condition should be searched in patients with CLIPPERS, especially in those presenting with atypical findings.

23 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LRLaura Rozenblum
Laura Rozenblum
CHCaroline Houillier
Caroline Houillier
CSCarole Soussain
Carole Soussain
MBMarc Bertaux
Marc Bertaux
SCSylvain Choquet
Sylvain Choquet
AKAurelie Kas
Aurelie Kas
The incidence of primary central nervous system lymphoma has increased over the past two decades in immunocompetent patients and the prognosis remains poor. A diagnosis and complete evaluation of the patient is needed without delay, but histologic evaluation is not always available and PCNSL can mimic a variety of brain lesions on MRI. In this article, we review the potential role of 18F-FDG PET for the diagnosis of PCNSL in immunocompetent and immunocompromised patients. Its contribution to systemic assessment at the time of diagnosis has been well established by expert societies over the past decade. In addition, 18F-FDG provides valuable information for differential diagnosis and outcome prediction. The literature also shows the potential role of 18F-FDG as a therapeutic evaluation tool during the treatment and the end of the treatment. Finally, we present several new radiotracers that may have a potential role in the management of PCNSL in the future.

12 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAndrea Morales Martinez
Andrea Morales Martinez
FLFernando Lozano
Fernando Lozano
ADAlberto Duran-Peña
Alberto Duran-Peña
KHKhe Hoang-Xuan
Khe Hoang-Xuan
CHCaroline Houillier
Caroline Houillier
The management of elderly patients suffering from primary central nervous system (CNS) lymphoma, who represent a rapidly growing population, is challenging. Despite the advances made in PCNSL treatment, the prognosis in older patients remains unsatisfactory. The high risk of systemic and CNS toxicity induced by a high-dose chemotherapy regimen and radiation therapy, respectively, limits the use of consolidation phase treatments in elderly patients and contributes to the poor outcome of these patients. Here, we review the current treatment strategies and ongoing trials proposed for elderly PCNSL patients.

10 April 2023 in Revue Neurologique
Verified
Journal Article
Closed access
ARA. Rachdi
A. Rachdi
HHH. Hernandez-Tost
H. Hernandez-Tost
DHD. Herzi
D. Herzi
AMA. Morales-Martinez
A. Morales-Martinez
IHI. Hernández-Verdin
I. Hernández-Verdin
KHKhe Hoang-Xuan
Khe Hoang-Xuan

22 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MRMonica Ribeiro
Monica Ribeiro
ABAmine Amine Benadjaoud
Amine Amine Benadjaoud
LMLaura Moisy
Laura Moisy
JJJulian Jacob
Julian Jacob
LFLoic Feuvret
Loic Feuvret
DRDamien Ricard
Damien Ricard
High-grade glioma (HGG) is associated with several external and internal stressors that may induce mood alterations at all stages of the disease. Symptoms of depression and anxiety in persons with glioma have multifactorial etiology and require active follow-up. We reviewed the literature data on the prevalence, mechanisms likely involved in the etiology of mood alterations in persons with HGG and psychosocial interventions found beneficial in treating these symptoms. We also investigated the prevalence and clinical variables that could increase the risk of depression and anxiety symptoms in a group of patients with HGG at two disease time-points: after surgery, before and 1 year after chemoradiotherapy. Literature findings revealed complex mechanisms underlying these symptoms and highlighted the importance of providing early access to palliative care. Our results show a high rate of anxiety and depression symptoms in the first stage of the disease and increased concomitance of these symptoms at the 1-year follow-up. Depression and anxiety symptoms at 1 year after the end of chemoradiotherapy were associated with the presence of symptoms at the first stage of the disease and tumor progression. Antiepileptic drugs and corticosteroid intake did not increase the risk of depressive and anxious symptoms among patients. Active management of mood alterations is an essential part of the care and contributes to patients’ well-being and quality of life.